Ordering
Available Variants10 mg
CHA.74273-10mg
Price
€75.04
Available – Dispatch in 14 days
50 mg
CHA.74273-50mg
Price
€301.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.74273-10mg | €75.04 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.74273-50mg | €301.60 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H20ClF2N3O3S |
|---|---|
| CAS Number | 1235560-28-7 |
| Molecular Weight | 455.91 |
| MDL number | MFCD29924737 |
| NACRES | NA.21 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H315 |
| pcodes | P264 - P280 - P301 + P312 - P302 + P352 - P332 + P313 - P362 + P364 |
| Hazard Classifications | Acute Tox. 4 Oral - Skin Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
ABT-639, also known by its CAS number 1235560-28-7, is a potent and selective orexin receptor antagonist. It has been investigated for its potential therapeutic applications, particularly in the treatment of sleep disorders and other conditions related to orexin dysregulation. The compound exhibits high affinity for both orexin 1 and orexin 2 receptors, which are involved in regulating arousal, wakefulness, and appetite. ABT-639 has demonstrated efficacy in preclinical models of insomnia and other sleep disorders, suggesting its potential as a novel therapeutic agent. Further research is needed to fully elucidate the pharmacological profile and clinical potential of ABT-639, but its unique mechanism of action and promising preclinical data make it an interesting candidate for further development and study. Its pharmacokinetic properties also support its potential for once-daily dosing.
